ES2130120T3 - Procedimiento para la preparacion de la adnasa humana. - Google Patents

Procedimiento para la preparacion de la adnasa humana.

Info

Publication number
ES2130120T3
ES2130120T3 ES90901443T ES90901443T ES2130120T3 ES 2130120 T3 ES2130120 T3 ES 2130120T3 ES 90901443 T ES90901443 T ES 90901443T ES 90901443 T ES90901443 T ES 90901443T ES 2130120 T3 ES2130120 T3 ES 2130120T3
Authority
ES
Spain
Prior art keywords
procedure
preparation
human dnase
human
dnasa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90901443T
Other languages
English (en)
Inventor
Steven Shak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26965935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2130120(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2130120T3 publication Critical patent/ES2130120T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)

Abstract

SE FACILITA ADN AISLADO QUE CODIFICA DNASA HUMANA Y METODOS PARA OBTENER ESTE ADN, JUNTO CON SISTEMAS DE EXPRESION PARA PRODUCCION RECOMBINANTE DE DNASA HUMANA EN COMPOSICIONES TERAPEUTICAS O DIAGNOSTICOS.
ES90901443T 1988-12-23 1989-12-20 Procedimiento para la preparacion de la adnasa humana. Expired - Lifetime ES2130120T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28995888A 1988-12-23 1988-12-23
US44803889A 1989-12-08 1989-12-08

Publications (1)

Publication Number Publication Date
ES2130120T3 true ES2130120T3 (es) 1999-07-01

Family

ID=26965935

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90901443T Expired - Lifetime ES2130120T3 (es) 1988-12-23 1989-12-20 Procedimiento para la preparacion de la adnasa humana.

Country Status (11)

Country Link
US (3) US20030044403A1 (es)
EP (2) EP0449968B1 (es)
JP (2) JP3162372B2 (es)
AT (2) ATE176924T1 (es)
AU (1) AU630658B2 (es)
BG (1) BG62870B2 (es)
CA (1) CA2006473C (es)
DE (2) DE68928934T2 (es)
ES (1) ES2130120T3 (es)
HU (1) HU211232A9 (es)
WO (1) WO1990007572A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007572A1 (en) * 1988-12-23 1990-07-12 Genentech, Inc. HUMAN DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
DE69535787D1 (de) 1994-03-04 2008-08-28 Genentech Inc Verbesserte dnase flüssige lösungen
WO1995023613A1 (en) * 1994-03-04 1995-09-08 Genentech, Inc. PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
WO1995030428A1 (en) * 1994-05-05 1995-11-16 Human Genome Sciences, Inc. Human dnase
US5821103A (en) * 1994-09-06 1998-10-13 Tanuma; Sei-Ichi Deoxyribonuclease
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
SK284191B6 (sk) * 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
CZ288633B6 (cs) * 1995-02-24 2001-08-15 Genentech, Inc. Na aktin rezistentní varianta lidské DNázy I a izolovaná nukleová kyselina ji kódující
DE19521046C1 (de) * 1995-06-09 1996-08-08 Deutsches Krebsforsch Protein mit DNase-Aktivität
PT854927E (pt) * 1995-10-10 2008-09-08 Genentech Inc Variantes da adnase i humana
AU727310B2 (en) * 1996-02-05 2000-12-07 Genentech Inc. Human DNASE resistant to actin inhibition
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6265195B1 (en) * 1996-04-25 2001-07-24 Genentech, Inc. Human DNase II
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
DE60035851D1 (de) 1999-08-17 2007-09-20 Tanuma Deoxyribonuklease, dafür kodierendes gen und verfahren
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
DK1578771T3 (da) 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
DE60335602D1 (de) 2002-12-18 2011-02-17 Roche Diagnostics Gmbh Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
EP1433842B1 (en) * 2002-12-18 2011-01-05 Roche Diagnostics GmbH Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
US7803777B2 (en) 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
PL1615689T3 (pl) 2003-04-09 2016-06-30 Novartis Ag Urządzenie do aerozolizacji z prowadnicą wyrównującą do przebijania kapsułki
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
AU2004293103C1 (en) 2003-11-24 2010-12-02 Ratiopharm Gmbh Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
CN101072789B (zh) 2004-01-08 2013-05-15 生物种属学股份公司 肽的o-连接的糖基化
US20080305518A1 (en) 2004-05-04 2008-12-11 Novo Nordisk Healthcare A/G O-Linked Glycoforms Of Polypeptides And Method To Manufacture Them
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
MX2007008229A (es) 2005-01-10 2007-09-11 Neose Technologies Inc Factor estimulador de colonias de granulocitos glicopegilado.
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
EP2086642B1 (en) 2006-10-18 2014-06-25 Periness Ltd. Dnase for the treatment of male sub-fertility
US8871200B2 (en) * 2006-11-28 2014-10-28 Cls Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
JP2010523582A (ja) 2007-04-03 2010-07-15 バイオジェネリクス アクチェンゲゼルシャフト グリコｐｅｇ化ｇ−ｃｓｆを用いた治療方法
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
WO2012106264A2 (en) * 2011-01-31 2012-08-09 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
US20160030527A1 (en) * 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Compositions and Methods for Treatment of Stroke
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
ES2759252T3 (es) * 2013-10-31 2020-05-08 Resolve Therapeutics Llc Fusiones y métodos terapéuticos de nucleasa-albúmina
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
EP3214172B1 (en) * 2014-10-31 2019-02-13 JCR Pharmaceuticals CO., LTD. Method for producing remcombinant human dnasei
RU2017125957A (ru) 2015-01-04 2019-02-04 Проталикс Лтд. Модифицированная днказа и ее применения
WO2016118476A1 (en) 2015-01-20 2016-07-28 The Children's Medical Center Corporation Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
JP6745873B2 (ja) 2015-05-22 2020-08-26 ドミトリエヴィッチ ゲンキン，ドミトリー 神経変性における治療標的としての細胞外ｄｎａ
DE102015118011A1 (de) * 2015-10-22 2017-04-27 Human Med Ag Vorrichtung zur Transplantation von Körperfett
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CN110199016B (zh) 2016-11-17 2024-08-16 艾欧凡斯生物治疗公司 残余肿瘤浸润淋巴细胞及其制备和使用方法
EP3351263A1 (en) * 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
AU2019209770A1 (en) * 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
CN116635056A (zh) 2020-10-07 2023-08-22 波塔力克斯有限公司 长效脱氧核糖核酸酶
US11993792B2 (en) 2021-05-27 2024-05-28 New England Biolabs, Inc. DNase I variants, compositions, methods, and kits

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Boen T. Khouw Isolation and purification of deoxyribonuclease
JPS55131389A (en) * 1979-04-02 1980-10-13 Amano Pharmaceut Co Ltd Purification of deoxyribonuclease i
WO1990007572A1 (en) * 1988-12-23 1990-07-12 Genentech, Inc. HUMAN DNase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
US6251648B1 (en) * 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase

Also Published As

Publication number Publication date
US20050009056A1 (en) 2005-01-13
DE68929551T2 (de) 2008-03-06
EP0853121A2 (en) 1998-07-15
EP0853121B1 (en) 2007-03-28
DE68928934D1 (de) 1999-04-01
WO1990007572A1 (en) 1990-07-12
AU630658B2 (en) 1992-11-05
BG62870B2 (bg) 2000-09-29
DE68929551D1 (de) 2007-05-10
ATE358176T1 (de) 2007-04-15
AU4826590A (en) 1990-08-01
US20030044403A1 (en) 2003-03-06
ATE176924T1 (de) 1999-03-15
EP0449968B1 (en) 1999-02-24
CA2006473C (en) 2002-02-05
US20080026426A1 (en) 2008-01-31
US7297526B2 (en) 2007-11-20
JP2001157580A (ja) 2001-06-12
JPH04502406A (ja) 1992-05-07
JP3162372B2 (ja) 2001-04-25
DE68928934T2 (de) 1999-08-05
EP0449968A1 (en) 1991-10-09
HU211232A9 (en) 1995-11-28
CA2006473A1 (en) 1990-06-23
EP0853121A3 (en) 1998-08-05

Similar Documents

Publication Publication Date Title
ES2130120T3 (es) Procedimiento para la preparacion de la adnasa humana.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
FI946004A (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
DE3650396D1 (de) Hirudinderivate.
ES2059547T3 (es) Expresion y secrecion mejoradas de proteinas heterologas en levadura, empleando secuencia conductora de factor alfa truncado.
ES2061512T3 (es) Polipeptidos de nor-estatina y nor-cicloestatina.
IT8467445A1 (it) Composizione e preparato per la somministrazione di medicamenti per via cutanea.
FI852626A0 (fi) Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
DK215287D0 (da) Dna-sekvenser, der koder for et protein med angiogen virkning, vektorer, vaertsceller og fremgangsmaader til udtrykkelse af proteinet, samt laegemidler indeholdende dette
ATE54826T1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
ES2070116T3 (es) Peptidos que inhiben la union del factor von willebrand.
GR1000172B (el) Βελτιωσεις εις η εν σχεσει προς τις σωματοστατινες.
FI864597A0 (fi) Kardiotoniska tiazoloner.
FI854074L (fi) Peptid-substituerade heterocykliska immunostimulanter.
DE3863200D1 (de) In der krebstherapie verwendbare zusammensetzung auf der basis von aminosaeure und vitaminen.
ES2056872T3 (es) Proteina pp4-x anticoagulante, su preparacion y empleo.
DE3686472D1 (de) Cardiotonische phenyloxazolone.
AR011110A1 (es) Promotor del gen de endoglina humana, una construccion de acido nucleico que comprende al menos una secuencia promotora del gen de endoglina humana, unacelula que alberga dicha construccion de acido nucleico, y el uso de dicha construccion de acido nucleico para preparar un farmaco
ATE69549T1 (de) Erzeugnisse, enthaltend gallopamil und prazosin.
IT8459312V0 (it) Massaggiatore manuale in fibra intrecciata di tipo perfezionato.
SE8500643D0 (sv) Konstruktionselement
IT1216188B (it) Strumento indicatore del grado di abbronzatura dell'epidermide.
MX20B (es) Mejoras en agujas utilizadas en electropuntura o galvanopuntura
ATE70971T1 (de) Foerderung der heilung von meniskusgewebe.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 449968

Country of ref document: ES